Search Results - "Colen, R.R"

Beam Path Toxicity in Candidate Organs at Risk: Assessment of Radiation Emetogenesis for Patients Receiving Head and Neck Intensity Modulated Radiation Therapy by Kocak, E, Gunn, B.G, Colen, R.R, Rosenthal, D.I, Clifton, F.D

Get full text

Evolving Role and Translation of Radiomics and Radiogenomics in Adult and Pediatric Neuro-Oncology by Ak, M, Toll, S A, Hein, K Z, Colen, R R, Khatua, S

“…Exponential technologic advancements in imaging, high-performance computing, and artificial intelligence, in addition to increasing access to vast amounts of…”
Get full text

Pembrolizumab in advanced rare cancers by Naing, A., Meric-Bernstam, F., Karp, D., Rodon, J.A., Piha-Paul, S.A., Subbiah, V., Hong, D.S., Pant, S., Fu, S., Janku, F., Yap, T.A., Tsimberidou, A.M., Dumbrava, E E Ileana, Colen, R.R., Hess, K.R., Campbell, M.T., Tu, S.-M., Jimenez, C., Habra, M.A., Varadhachary, G.R.

Get full text

1270P - Pembrolizumab in advanced rare cancers by Naing, A., Meric-Bernstam, F., Karp, D., Rodon, J.A., Piha-Paul, S.A., Subbiah, V., Hong, D.S., Pant, S., Fu, S., Janku, F., Yap, T.A., Tsimberidou, A.M., Dumbrava, E E Ileana, Colen, R.R., Hess, K.R., Campbell, M.T., Tu, S.-M., Jimenez, C., Habra, M.A., Varadhachary, G.R.

“…Patients with rare cancers account for 25% of cancer-related deaths but have limited treatment options. As immunotherapy has potential applicability across…”
Get full text

Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1 by Naing, A., Papadopoulos, K.P., Autio, K.A., Ott, P.A., Patel, M.R., Wong, D.J., Falchook, G., Pant, S., Whiteside, M., Rasco, D., Patnaik, A., Bendell, J.C., Bauer, T.M., Colen, R.R., Hong, D., Van Vlasselaer, P., Brown, G.L., Oft, M., Tannir, N., Infante, J.R.

Get full text